Discovery of novel and potent InhA inhibitors by an in silico screening and pharmacokinetic prediction. (2022)
Attributed to:
Nicotinic Ligand Development to Target Smoking Cessation and Gain a Molecular Level Understanding of Partial Agonism
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.4155/fmc-2021-0348
PubMed Identifier: 35485258
Publication URI: http://europepmc.org/abstract/MED/35485258
Type: Journal Article/Review
Volume: 14
Parent Publication: Future medicinal chemistry
Issue: 10
ISSN: 1756-8919